Lokalize Vitiligo ve Psoriazis Lezyonlarının Tedavisinde Mikrofototerapinin Etkinliğini Değerlendiren Prospektif Klinik Çalışma
Özet
Psoriasis and vitiligo are autoinflammatory/autoimmune chronic skin diseases. Treatment is not always possible to easily in these diseases which can lead significant morbidity. New treatment alternatives and methods to reduce the side effects are required. Microphototherapy method has been recently started to use for the treatment of psoriasis and vitiligopatients with a limited number of lesions.Despite the application of systemic and topical treatments, who have still recalcitrant lesions or these treatments are contraindicated, considering long-term side effects of phototherapy, microphototherapy method gains currency. Thus, we planned this trial to evaluate the effectiveness of this treatment and to predict the success of a new treatment option for localised vitiligo and psoriasis lesions.This study is carried out as a prospective study thrice weekly for at least 50 sessions.In this study, we used MedLight CupCUBEGrimed® microphototherapy device with its UVB spectrum emitting property for plaque psoriasis and vitiligo patients with lesions instead of face and genitalia area localisation. 37 patients with 23 psoriasis and 14 vitiligo completed study.Local Psoriasis Severity Index(PSI) were calculated on psoriasis group, Vitiligo Area Scoring Index(VASI) was calculated on vitiligo group at the beginning, at 36. and 50 sessions. With treatment PSI scores on psoriasis, VASI scores on vitiligo patients decreased. PSI rates decreased significantly; however VASI rates didn't decrease significantly. The MedLight CupCUBEGrimed® microphototherapy device is an effective, safe method for the treatment of focal, localised lesions of psoriasis and vitiligo. The most important advantages are providing exposure of involved areas, sparing of uninvolved areas and thus minimizing total radiation dose. But requiring experienced personnel, taking a long timeand high cost of treatment are disadvantages.